POS-359 Developing targeted therapies for kidney disease in public private partnerships

Abstract

Integrating public and private research efforts is key to expediting precision medicine for glomerular diseases. The Nephrotic Syndrome Study Network (NEPTUNE) has developed an innovative research and business model: “MATCH”, to enable targeted patient enrollment in clinical trials via the NEPTUNE public private partnership (NP5). The NEPTUNE community knowledge base is leveraged to identify a molecular signal matching therapeutic targets under development by NP5 industry partners. The three steps of MATCH are: (1) predictive biomarker development; (2)patient communication about precision medicine; and (3) return of results from NP5 partner clinical trials for evaluation of patient stratification effects on trial outcomes. MATCH begins with NEPTUNE patient education on risks and benefits of the study. Once enrolled in MATCH, a patient’s biosamples undergo biomarker profiling. MATCH provides individual pathway activation information to patients for consideration in their independent decision to enroll in a trial that may be more tailored to their specific disease and stage. Finally, clinical trial outcomes will be reported by NP5 partners to NEPTUNE to evaluate the MATCH impact on treatment responses. MATCH aims to assess the ability to communicate molecular information to patients, and to test precision medicine across multiple trials and partners to move science closer to the overall goal: reaching the right patient with the right medicine at the right time. MATCH is an open framework available to additional partners interested in joining NP5.